Literature DB >> 24322598

Breast cancer: updated guideline recommendations for HER2 testing.

Emad A Rakha1, Ian O Ellis1.   

Abstract

The recently updated HER2 testing guidelines by ASCO and the College of American Pathologists (CAP) are a significant step towards personalized medicine. It is excellent news that such great effort has been put into standardizing biomarker assessment. Undoubtedly, these recommendations will improve the analytical validity of HER2 testing, its clinical utility and the communication among health-care providers.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24322598     DOI： 10.1038/nrclinonc.2013.230

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  10 in total

1.  Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.

Authors:  Lavinia P Middleton; Kathy M Price; Pamela Puig; Lori J Heydon; Emily Tarco; Nour Sneige; Kaye Barr; Michael T Deavers
Journal:  Arch Pathol Lab Med       Date:  2009-05       Impact factor: 5.534

2.  HER2 status and benefit from adjuvant trastuzumab in breast cancer.

Authors:  Soonmyung Paik; Chungyeul Kim; Norman Wolmark
Journal:  N Engl J Med       Date:  2008-03-27       Impact factor: 91.245

3.  HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations.

Authors:  Jane Starczynski; Neil Atkey; Yvonne Connelly; Tony O'Grady; Fiona M Campbell; Silvana di Palma; Peter Wencyk; Bharat Jasani; Michael Gandy; J M S Bartlett
Journal:  Am J Clin Pathol       Date:  2012-04       Impact factor: 2.493

4.  Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

Authors:  Edith A Perez; Edward H Romond; Vera J Suman; Jong-Hyeon Jeong; Nancy E Davidson; Charles E Geyer; Silvana Martino; Eleftherios P Mamounas; Peter A Kaufman; Norman Wolmark
Journal:  J Clin Oncol       Date:  2011-07-18       Impact factor: 44.544

5.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

6.  Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast.

Authors:  Andrew H S Lee; Heather P Key; Jane A Bell; Zsolt Hodi; Ian O Ellis
Journal:  Histopathology       Date:  2012-02-09       Impact factor: 5.087

7.  Prognostic significance of Nottingham histologic grade in invasive breast carcinoma.

Authors:  Emad A Rakha; Maysa E El-Sayed; Andrew H S Lee; Christopher W Elston; Matthew J Grainge; Zsolt Hodi; Roger W Blamey; Ian O Ellis
Journal:  J Clin Oncol       Date:  2008-05-19       Impact factor: 44.544

Review 8.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

Authors:  M Elizabeth H Hammond; Daniel F Hayes; Mitch Dowsett; D Craig Allred; Karen L Hagerty; Sunil Badve; Patrick L Fitzgibbons; Glenn Francis; Neil S Goldstein; Malcolm Hayes; David G Hicks; Susan Lester; Richard Love; Pamela B Mangu; Lisa McShane; Keith Miller; C Kent Osborne; Soonmyung Paik; Jane Perlmutter; Anthony Rhodes; Hironobu Sasano; Jared N Schwartz; Fred C G Sweep; Sheila Taube; Emina Emilia Torlakovic; Paul Valenstein; Giuseppe Viale; Daniel Visscher; Thomas Wheeler; R Bruce Williams; James L Wittliff; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2010-04-19       Impact factor: 44.544

9.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

Review 10.  HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.

Authors:  Wedad M Hanna; Josef Rüschoff; Michael Bilous; Renata A Coudry; Mitch Dowsett; Robert Y Osamura; Frédérique Penault-Llorca; Marc van de Vijver; Giuseppe Viale
Journal:  Mod Pathol       Date:  2013-06-28       Impact factor: 7.842
  10 in total
  5 in total

1.  A microfluidic platform with digital readout and ultra-low detection limit for quantitative point-of-care diagnostics.

Authors:  Ying Li; Jie Xuan; Yujun Song; Ping Wang; Lidong Qin
Journal:  Lab Chip       Date:  2015-08-21       Impact factor: 6.799

2.  New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.

Authors:  N Tchrakian; L Flanagan; J Harford; J M Gannon; C M Quinn
Journal:  Virchows Arch       Date:  2015-10-31       Impact factor: 4.064

3.  Subclonal diversification of primary breast cancer revealed by multiregion sequencing.

Authors:  Lucy R Yates; Moritz Gerstung; Stian Knappskog; Christine Desmedt; Gunes Gundem; Peter Van Loo; Turid Aas; Ludmil B Alexandrov; Denis Larsimont; Helen Davies; Yilong Li; Young Seok Ju; Manasa Ramakrishna; Hans Kristian Haugland; Peer Kaare Lilleng; Serena Nik-Zainal; Stuart McLaren; Adam Butler; Sancha Martin; Dominic Glodzik; Andrew Menzies; Keiran Raine; Jonathan Hinton; David Jones; Laura J Mudie; Bing Jiang; Delphine Vincent; April Greene-Colozzi; Pierre-Yves Adnet; Aquila Fatima; Marion Maetens; Michail Ignatiadis; Michael R Stratton; Christos Sotiriou; Andrea L Richardson; Per Eystein Lønning; David C Wedge; Peter J Campbell
Journal:  Nat Med       Date:  2015-06-22       Impact factor: 53.440

4.  Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.

Authors:  Zsuzsanna Varga; Aurelia Noske
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

Review 5.  Mechanisms of Therapeutic Antitumor Monoclonal Antibodies.

Authors:  Li-Chung Tsao; Jeremy Force; Zachary C Hartman
Journal:  Cancer Res       Date:  2021-06-18       Impact factor: 13.312
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.